UK markets closed

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.10-0.35 (-3.70%)
At close: 04:00PM EDT
9.10 +0.00 (+0.00%)
After hours: 06:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.45
Open9.36
Bid9.08 x 3200
Ask9.11 x 2300
Day's range8.44 - 9.45
52-week range1.76 - 15.21
Volume4,519,442
Avg. volume4,659,803
Market cap1.046B
Beta (5Y monthly)1.14
PE ratio (TTM)N/A
EPS (TTM)-3.78
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est18.00
  • GlobeNewswire

    Arcutis Appoints David Topper as Chief Financial Officer

    Industry veteran with over 40 years of experience in finance, investment management, and investment bankingWESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that David Topper has been appointed Chief Financial Officer (CFO) effective April 10, 2024. He is replacing John Smither, who rejoined Arcutis as interim CFO in August 2023.

  • Zacks

    Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

    Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

  • GlobeNewswire

    Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 58,500 restricted stock units of Arcutis’ common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Induc